AngioDynamics (NASDAQ:ANGO) updated its FY 2020 earnings guidance on Wednesday. The company provided earnings per share guidance of $0.25-0.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.25. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.58 million.AngioDynamics also updated its FY20 guidance to $0.25-0.30 EPS.

A number of research firms recently weighed in on ANGO. BidaskClub raised Westport Fuel Systems from a hold rating to a buy rating in a research note on Friday. ValuEngine downgraded Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Zacks Investment Research raised Investar from a hold rating to a buy rating and set a $27.00 price target on the stock in a research note on Tuesday, June 4th. Finally, TheStreet lowered Upland Software from a b- rating to a c+ rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $21.50.

ANGO stock opened at $21.68 on Friday. The company has a market capitalization of $814.66 million, a price-to-earnings ratio of 26.69 and a beta of 0.69. The company has a current ratio of 4.30, a quick ratio of 1.70 and a debt-to-equity ratio of 0.20. The firm has a 50 day simple moving average of $19.62. AngioDynamics has a 12-month low of $18.11 and a 12-month high of $25.48.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.01). The business had revenue of $96.30 million during the quarter, compared to the consensus estimate of $92.34 million. AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The business’s revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.20 earnings per share. On average, equities research analysts anticipate that AngioDynamics will post 0.27 earnings per share for the current year.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Featured Article: What is a management fee?

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with's FREE daily email newsletter.